UHRF1 and colonic neoplasm: A functional UHRF1 SRA domain, as evaluated by point mutations that disrupt DNA interaction, is required for sustaining the oncogenic activity of UHRF1 in colon cancer cells (18), adding to the motivation of UHRF1 SRA antagonism as a cancer therapeutic strategy (19).